問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberEB057-PMS-01
Active

2024-08-01 - 2029-12-31

Others

Recruiting9

ICD-10I27.0

Primary pulmonary hypertension

ICD-9416.0

Primary pulmonary hypertension

  • Trial Applicant

    EXCELSIOR BIOPHARMA INCORPORATION

  • Sponsor

  • Trial scale

    Taiwan Multiple Center

  • Update

    2026/04/01

Investigators and Locations

Principal Investigator 吳懿哲 Division of Cardiovascular Diseases

Co-Principal Investigator

  • 吳書豪 Division of Cardiovascular Diseases

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 林坤璋 Division of Cardiovascular Diseases

Co-Principal Investigator

  • 郭書宏 Division of Cardiovascular Diseases
  • 楊弘州 Division of Cardiovascular Diseases

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 黃祺耀 Division of Cardiovascular Diseases

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Kuo-Yang Wang Division of Cardiovascular Diseases

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chih-Hsin Hsu Division of Cardiovascular Diseases

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator

Co-Principal Investigator

  • 黃偉春 Division of Cardiovascular Diseases

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Shih-Hsien Sung Division of Cardiovascular Diseases

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Wan-Jing Ho Division of Cardiovascular Diseases

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 鄭錦昌 Division of Cardiovascular Diseases

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    20 participants

  • Global

    NA participants